Isolated clathrin therapeutics

Abstract

The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or one or more type of therapeutic agent for treating a disease, condition, or disorder comprising a cell element or a cell process in vivo or in vitro.

1 . A pharmaceutical composition comprising: a manmade self-assembling purified clathrin heavy chain protein for use in targeting and/or treating a clathrin protein associated disease, condition, or disorder. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the clathrin heavy chain protein is an amino acid sequence (SEQ ID NO: 1) between 1 and 1675 amino acids, inclusive. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the clathrin heavy chain protein is an amino acid sequence (SEQ ID NO: 2) between 1 and 1640 amino acids, inclusive. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the self-assembling clathrin protein is a purified clathrin protein. 
     
     
         5 . The pharmaceutical composition of  claim 1 , further comprising a clathrin light chain protein disposed adjacent to the clathrin heavy chain. 
     
     
         6 . The pharmaceutical composition of  claim 1 , further comprising one or more adaptor protein disposed adjacent to the clathrin heavy chain. 
     
     
         7 . The pharmaceutical composition of  claim 1 , further comprising one or more masking moiety disposed adjacent to the clathrin heavy chain. 
     
     
         8 . The isolated bio-nanoplatform of  claim 1 , wherein the clathrin protein comprises self-assembling biologically active, biologically modified, chiral, genetically modified, hybridized, chemically modified, recombinant, synthetic or unmasked protein molecules, or a combination thereof. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the clathrin protein is stable in serum. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the clathrin protein is non-immunogenic or non-toxic, or a combination thereof. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the clathrin protein associated disease, condition, or disorder is an intracellular communication, extracellular communication, degradation, endocytosis, exocytosis, genetic, genotype, membrane trafficking, metabolic, mitosis, nutritional, organelle, phenotype, receptor downregulation, receptor upregulation, recycling, signaling, tracking, trafficking, transcription or a vesicle disease, condition, or disorder. 
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein the clathrin heavy chain is capable of comprising a compound protein. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein three of the clathrin protein is capable of forming a clathrin triskelion. 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein the clathrin protein is capable of non-invasively targeting and/or crossing a biological barrier. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the biological barrier is an anal, blood brain, blood-cerebrospinal, blood vessel, capillary, cell, cell membrane, circumventricular, epithelial, extracellular, fenestrated capillary, fenestrated vessel, intracellular, intramuscular, lipid, lymphatic, nasal, nasal cavity, nasal mucosa, ocular, olfactory epithelium, olfactory nerve, oral, membrane protein, organelle, paracellular, perineural space, plasma membrane, skin, subarachnoid, subcutaneous, tight junction, trigeminal nerve, vomeronasal or a vesicle barrier. 
     
     
         16 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated for any suitable route and means of administration. 
     
     
         17 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated as an adhesive, aerosols, a biologic, a capsule, a chemical compound, eye drops, gels, an injectable, liquids, oils, ointments, a prosthetic, salves, soft galantine capsules, a stent, a controlled release, subcutaneous, surgical, syrups, a tablet, a topical, a vapor, or a water soluble composition. 
     
     
         18 . The pharmaceutical composition of  claim 1 , further comprising a therapeutic agent. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the therapeutic agent is a clathrin protein drug. 
     
     
         20 . The pharmaceutical composition of  claim 1 , comprising multiple purified clathrin heavy chain proteins. 
     
     
         21 . A method of treating a disease, condition, or disorder comprising: administering to a subject in need thereof a protein or composition according to  claim 1 , wherein the disease, condition, or disorder is a clathrin protein associated disease, condition, or disorder. 
     
     
         22 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is further capable of comprising a ligand.